Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

By J. Sampson, A. Heimberger, G. Archer, Kenneth D. Aldape, A. Friedman, H. Friedman, M. Gilbert, J. Herndon, R. McLendon, D. Mitchell and 6 more. Journal of Clinical Oncology, 2010

776 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/87bd41f17f457b9567ba8acaade59123679343fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Guido Reifenberger
2. Michael Weller

Citations in the corpus

• Glioblastoma: pathology, molecular mechanisms and markers (2015, result): “Initial results from single-arm trials employing EGFRvIII-specific vaccination provided promising results in comparison to historical controls [138].”
• Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A Report of the RANO Working Group (2015, background): “Nonetheless, anecdotal reports of glioma patients treated with tumor vaccination therapy have described pseudoprogressive radiographic findings that also typically manifest within six months of treatment initiation.(25,36,38)”
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma (2015, background): “The recurrence of antigen-negative GBM is not unique to our study or specific for CAR T-cell immunotherapy, since it has also been observed following EGFRvIII-targeted vaccination strategies (28, 29).”